Health Condition 1: null- Hair loss in females
Conditions
Interventions
Intervention1: MAR/HO-02 Oil: MAR/HO-02 Oil Contains Amla (Emblica officinalis), Mehandi (Lawsania ineris), Methi (Trigonella foenum graecum), Kumari (Aloe vera), Musta (Cyperus rotundus) processed in
Sponsors
Marico Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects suffering from mild to moderate hair loss (by comb test). 2. Subjects who are infrequent hair oil users 3. Subjects who are willing to give informed consent and ready to comply with the protocol 4. Subjects who are ready to provide regular follow ups till the completion of the study
Exclusion criteria
Exclusion criteria: 1. Subjects with severe Hair fall due to any clinically significant disorders like anemia, thyroid disorders etc. 2. Subject with severe dermatological disorders of the scalp that might interfere with the study evaluation 3. Subjects with recent disease history like, malaria, typhoid, jaundice and scalp diseases and subjects who in the opinion of the investigator are not eligible for enrollment in the clinical study 4. Subjects who have regularly used anti-hair fall treatment with hair oils over the last 6 months. 5. Subjects who have previously undergone hair transplantation procedures 6. Subjects on systemic steroids for more than 14 days within 2 months prior to enrollment. 7. Subjects on immunosuppressive drugs 8. Known cases of Hypersensitivity to hair oil contents 9. Subjects who have participated in any other clinical study since last 3 months 10. Subjects who are reported pregnant or planning a pregnancy or lactating. 11. Menopausal Women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of efficacy of MAR/HO-02 oil in mild to moderate hair loss in females (by running finger test and comb test) Timepoint: Day -5, Day 0, Day 15, Day 30, Day 45 and Day 60 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Assessment of effect of MAR/HO-02 on quality of hair based on subject questionnaire including effect on dandruff, greying and hair growth. 2.Global assessment of overall change in hair loss by the physician 3.Global assessment of overall change in hair loss by the subject 4.Assessment of safety by observing episodes, severity and duration of any allergic reactions and adverse eventsTimepoint: Day -5, Day 0, Day 15, Day 30, Day 45 and Day 60 | — |
Countries
India
Contacts
Public ContactDr Sanjay Tamoli
Target Institute of Medical Education and Research
Outcome results
None listed